Wall Street brokerages forecast that X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) will announce earnings per share of ($0.68) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for X4 Pharmaceuticals’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.82). X4 Pharmaceuticals reported earnings per share of ($0.91) during the same quarter last year, which indicates a positive year over year growth rate of 25.3%. The company is scheduled to report its next earnings report on Thursday, March 3rd.
On average, analysts expect that X4 Pharmaceuticals will report full-year earnings of ($3.06) per share for the current year, with EPS estimates ranging from ($3.42) to ($2.79). For the next financial year, analysts expect that the firm will report earnings of ($2.78) per share, with EPS estimates ranging from ($3.93) to ($2.34). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow X4 Pharmaceuticals.
X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, November 4th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.04). During the same quarter in the prior year, the firm posted ($0.87) EPS.
A number of hedge funds have recently made changes to their positions in the business. Altium Capital Management LP bought a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth about $4,256,000. Marshall Wace LLP increased its holdings in shares of X4 Pharmaceuticals by 84.0% in the 3rd quarter. Marshall Wace LLP now owns 25,223 shares of the company’s stock worth $133,000 after buying an additional 11,514 shares during the last quarter. AXA S.A. increased its holdings in shares of X4 Pharmaceuticals by 3.8% in the 3rd quarter. AXA S.A. now owns 590,269 shares of the company’s stock worth $3,123,000 after buying an additional 21,853 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of X4 Pharmaceuticals by 10.0% in the 3rd quarter. Geode Capital Management LLC now owns 178,060 shares of the company’s stock worth $941,000 after buying an additional 16,143 shares during the last quarter. Finally, AIGH Capital Management LLC increased its holdings in shares of X4 Pharmaceuticals by 15.7% in the 3rd quarter. AIGH Capital Management LLC now owns 1,664,540 shares of the company’s stock worth $8,805,000 after buying an additional 225,641 shares during the last quarter. Institutional investors and hedge funds own 71.55% of the company’s stock.
Shares of XFOR traded down $0.08 during trading hours on Friday, reaching $2.09. 205,335 shares of the stock traded hands, compared to its average volume of 240,609. The company has a current ratio of 6.10, a quick ratio of 6.10 and a debt-to-equity ratio of 0.48. X4 Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $10.70. The company’s 50-day moving average price is $3.35 and its two-hundred day moving average price is $4.69. The company has a market cap of $51.64 million, a P/E ratio of -0.56 and a beta of 0.33.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.
Featured Story: What’s a Black Swan?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.